Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 376-383 , March 2010

New-Onset Lymphopenia Assessed during Routine Follow-up Is a Risk Factor for Relapse Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma

Received 10 September 2009 ,Accepted 26 October 2009.

References 

  1. Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ. The international prognostic index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant. 2007;13:486–492
  2. Huisman C, de Weger RA, de Vries L, Tilanus MGL, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant. 2007;39:285–291
  3. Lawler M, McCann SR, Marsh JCW, et al. Serial chimerism analysis indicate that mixed haematopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post-SCT for SAA. Br J Haematol. 2008;144:933–945
  4. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006;20:1690–1700
  5. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med. 2004;4:78–85
  6. Porrata LF. Clinical evidence of autologous graft versus tumor effect. Am J Immunol. 2009;5:1–7
  7. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586
  8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med. 1999;18:695–706
  9. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027–4034
  10. Ghosh D. Proportional hazards regression for cancer studies. Biometrics. 2008;64:141–148
  11. Porrata LF. Host immunity and survival. Leukemia Lymphoma. 2008;49:843–844
  12. Behl D, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab in follicular lymphomas. Br J Haematol. 2007;137:409–415
  13. Bensinger DT. Optimization of peripheral blood stem cell collection. Curr Opin Hematol. 1995;2:219–226
  14. Phillip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545
  15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  16. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  17. Costa LJ, Feldman Al, Micallef IN, et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol. 2008;142:404–412

 Financial disclosure: See Acknowledgments on page 382.

PII: S1083-8791(09)00510-2

doi: 10.1016/j.bbmt.2009.10.029

Biology of Blood and Marrow Transplantation
Volume 16, Issue 3 , Pages 376-383 , March 2010

Article Tools

* Image Usage & Resolution